NVAX stock forecast
Our latest prediction for Novavax, Inc.'s stock price was made on the Sept. 11, 2019 when the stock price was at 5.74$.
In the short term (2weeks), NVAX's stock price should underperform the market by -0.31%. During that period the price should oscillate between -10.17% and +15.47%.
In the medium term (3months), NVAX's stock price should underperform the market by -2.74%. During that period the price should oscillate between -23.96% and +38.77%.Get email alerts
About Novavax, Inc.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
At the moment the company generates 16M USD in revenues.
On its last earning announcement, the company reported a loss of -7.01$ per share.
The book value per share is -0.23$
Three months stock forecastSept. 11, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|